GlassScriptPhysician profile
Luke D Engelman
NPI 1669867008
$1,697.42
in general payments reported to CMS, 2019-2025
25 companies · $168 in 2025
The $168 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $169 · 2020: $169 · 2021: $194 · 2022: $240 · 2023: $246 · 2024: $511 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $925.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $409.95 | 2021-2025 | Qelbree |
| Glaxosmithkline, LLC. | $313.01 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Corium, LLC | $168.78 | 2021-2024 | Azstarys |
| Sanofi Pasteur INC. | $95.53 | 2019-2025 | |
| Cranial Technologies, INC | $91.94 | 2019-2024 | Doc Band |
| Merck Sharp & Dohme LLC | $85.52 | 2021-2025 | Gardasil 9, Proquad, Gardasil |
| Tris Pharma INC | $67.84 | 2019-2021 | |
| Pfizer INC. | $48.33 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.30 | 2019-2021 | |
| Sobi, INC | $44.11 | 2023 | |
| Seqirus USA INC | $39.45 | 2023-2025 | Flucelvax, Fluad Quadrivalent, Flucelvax Quadrivalent |
| Adlon Therapeutics L.P. | $37.33 | 2019-2020 | |
| Kaleo, INC. | $36.05 | 2022-2023 | Auvi-Q |
| Neos Therapeutics, LP | $28.83 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $23.63 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $22.86 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $17.80 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.60 | 2019 | |
| Genentech USA, INC. | $17.33 | 2020 | |
| Abbott Laboratories | $16.67 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.77 | 2020 | |
| Ucb, INC. | $14.61 | 2022 | |
| Sarepta Therapeutics, INC. | $14.19 | 2021 | |
| Biomarin Pharmaceutical INC. | $13.99 | 2025 | Voxzogo 1.2mg |
| Mylan Pharmaceuticals INC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Engelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.